Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy.
Nature communications
Li Y, Cong Y, Jia M, He Q, Zhong H, Zhao Y, Li H, Yan M, You J, Liu J, Chen L, Hang H, Wang S.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2021
Cancer Research
Immunology
No items found.
Key Finding
Notably, the fusion protein PD-1Ab21 promotes the generation of memory stem T cells (T SCM ) with enhanced cell proliferation. Therefore, the authors have developed a potential strategy to improve the therapeutic effects of immune checkpoint blockade by simultaneously targeting cytokines to tumor-reactive T cells.
Countstar Connection
Countstar (model not specified) quantified cell numbers in the study's cell samples during quality assessment in the 2021 Nature communications study.
